Skip to main content
SpringerLink
Log in

Reply to comment on “Demonstrating the value of cancer biomarkers at the population”

  • Reply
  • Published:
The European Journal of Health Economics Aims and scope Submit manuscript

The Original Article was published on 13 May 2022

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. As a recent example, MSD’s approval application of pembrolizumab (Keytruda) for treatment of esophageal cancer was initially for the all-comer population. However, the European Medicines Agency (EMA) accepted the indication in patients whose tumors express PD-L1 with a CPS ≥ 10 only, after concluding that the clinical effect on patients with CPS < 10 was not significant [2].

References

  1. Garrison, L.P., Towse, A.: Economics of personalised medicine: pricing and reimbursement policies as a potential barrier to development and adoption. In: Culyer, T. (ed.) Encyclopedia of Health Economics, Elsevier, Oxford, UK (2014)

    Chapter  Google Scholar 

  2. European Medicines Agency. Keytruda: EPA—Public assessment report 2021. Available from: https://www.ema.europa.eu/en/documents/variation-report/keytruda-h-c-3820-ii-0097-epar-assessment-report-variation_en.pdf

Download references

Author information

Authors and Affiliations

  1. Department of Economics, University of Bergen, Bergen, Norway

    Ana Beatriz D’Avó Luís

  2. Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK

    Mikyung Kelly Seo

  3. Centre for Cancer Biomarkers (CCBIO), Faculty of Medicine, University of Bergen, Bergen, Norway

    Ana Beatriz D’Avó Luís & Mikyung Kelly Seo

  4. Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK

    Mikyung Kelly Seo

Authors
  1. Ana Beatriz D’Avó Luís
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mikyung Kelly Seo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ana Beatriz D’Avó Luís.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Luís, A.B.D., Seo, M.K. Reply to comment on “Demonstrating the value of cancer biomarkers at the population”. Eur J Health Econ 23, 757–758 (2022). https://doi.org/10.1007/s10198-022-01475-5

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10198-022-01475-5

JEL Classifications

Search

Navigation